Article PDF first page preview

First page of Prognostic impact of recurrence pattern for surgically resected non-small cell lung cancer

Introduction: Although several prognostic risk factors have been identified for non-small cell lung cancer (NSCLC) patients who undergo pulmonary resection, the significance of several factors remains unclear, including the number and location of recurrent foci. Here, we investigated associations between clinicopathological characteristics and the risk of recurrence patterns. Methods: We retrospectively evaluated the prognostic impact of the recurrence pattern and individual recurrence sites for 1000 NSCLC patients who underwent pulmonary resection between 2002 and 2021. The recurrence was defined by imaging tools, and the data were analyzed using logistic regression and Cox proportional hazards regression models. Results: Simultaneous intra-thoracic and extra-thoracic recurrence was associated with significantly shorter overall survival compared with either recurrence pattern alone. Multivariate analyses identified significant risk factors for sites of recurrence as follows: age (P=0.03), prognostic nutrition index (P=0.03), lymphatic invasion (P=0.03), pathological lymph node metastasis (pN)1 (P=0.02), and pN2 (P<0.01) for bone metastasis; cancer-inflammation prognostic index (CIPI) (P=0.04), maximum standardized uptake value (SUVmax) (P<0.01), and pN2 (P<0.01) for brain metastasis; histological type without adenocarcinoma and squamous cell carcinoma (P<0.01) for liver metastasis; age (P<0.01), SUVmax (P<0.01), lower lobe (P<0.01), and pN2 (P<0.01) for lung metastasis; CIPI (P<0.01), SUVmax (P<0.01), Ly (P=0.01), pN1 (P<0.01), and pN2 (P=0.01) for lymph node metastasis; and CIPI (P<0.01) for pleural dissemination. Conclusion: Simultaneous intra-thoracic and extra-thoracic recurrence was a significant prognostic indicator of poor overall survival. Identification of the risk factors for each recurrence site may assist in planning optimal routine postoperative surveillance strategies.

Journal Section:
Clinical Study
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.